Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 May 27;16(5):e0251992.
doi: 10.1371/journal.pone.0251992. eCollection 2021.

Willingness to participate in COVID-19 vaccine trials; a survey among a population of healthcare workers in Uganda

Affiliations

Willingness to participate in COVID-19 vaccine trials; a survey among a population of healthcare workers in Uganda

Jonathan Kitonsa et al. PLoS One. .

Abstract

Background: Healthcare workers (HCWs) are at high risk of acquiring SARS-CoV-2 and COVID-19 and may therefore be a suitable population for COVID-19 vaccine trials. We conducted a survey to evaluate willingness-to-participate in COVID-19 vaccine trials in a population of HCWs at three hospitals in Uganda.

Methods: The survey was conducted between September and November 2020. Using a standardised questionnaire, data were collected on socio-demographics, previous participation in health research, COVID-19 information sources, underlying health conditions, and willingness-to-participate in COVID-19 vaccine trials. Data were analysed descriptively and a binomial generalised linear model with a log link function used to investigate factors associated with unwillingness to participate.

Results: 657 HCWs (female, 63%) were enrolled with a mean age of 33 years (Standard Deviation, 10). Overall willingness-to-participate was 70.2%. Key motivating factors for participation were: hope of being protected against COVID-19 (81.1%), altruism (73.3%), and the opportunity to get health care (26.0%). Selected hypothetical trial attributes reduced willingness-to-participate as follows: weekly-quarterly study visits over a 12-month period (70.2%-63.2%, P = 0.026); provision of approximately 50ml of blood at each study visit (70.2%-63.2%, P = 0.026); risk of mild-moderate local adverse reactions (70.2%-60.3%, P<0.001); chance of receiving candidate vaccine or placebo (70.2%-56.9%, P<0.001); and delay of pregnancy [Overall, 70.2%-57.1% P<0.001); Female, 62.8%-48.4% (P = 0.002); Male, 82.5%-71.5% (P = 0.003)]. Collectively, these attributes reduced willingness-to-participate from [70.2%-42.2% (P<0.001) overall; 82.5%-58.1% (P<0.001) in men; 62.8%-32.6% (P<0.001) in women]. Among individuals that were unwilling to participate, the commonest barriers were concerns over vaccine safety (54.6%) and fear of catching SARS-CoV-2 (31.6%). Unwillingness to participate was associated with being female (aRR 1.97, CI 1.46-2.67, P<0.001) and having university or other higher-level education (aRR 1.52, CI 1.05-2.2, P = 0.026).

Conclusions: Willingness-to-participate in COVID-19 vaccine trials among HCWs in Uganda is high but may be affected by vaccine trial requirements and concerns about the safety of candidate vaccines.

PubMed Disclaimer

Conflict of interest statement

The authors have declared that no competing interests exist.

References

    1. WHO. Weekly epidemiological update—23 March 2021 2021 [cited 2021 24/04/22021]. Available from: https://www.who.int/publications/m/item/weekly-epidemiological-update-on....
    1. Nicola M, Alsafi Z, Sohrabi C, Kerwan A, Al-Jabir A, Iosifidis C, et al.. The socio-economic implications of the coronavirus pandemic (COVID-19): A review. International Journal of Surgery. 2020;78:185–93. 10.1016/j.ijsu.2020.04.018 - DOI - PMC - PubMed
    1. Martin A, Markhvida M, Hallegatte S, Walsh B. Socio-Economic Impacts of COVID-19 on Household Consumption and Poverty. Economics of Disasters and Climate Change. 2020;4(3):453–79. 10.1007/s41885-020-00070-3 - DOI - PMC - PubMed
    1. Geleris J, Sun Y, Platt J, Zucker J, Baldwin M, Hripcsak G, et al.. Observational Study of Hydroxychloroquine in Hospitalized Patients with Covid-19. New England Journal of Medicine. 2020;382(25):2411–8. 10.1056/NEJMoa2012410 - DOI - PMC - PubMed
    1. Beigel JH, Tomashek KM, Dodd LE, Mehta AK, Zingman BS, Kalil AC, et al.. Remdesivir for the Treatment of Covid-19—Final Report. The New England journal of medicine. 2020:NEJMoa2007764. 10.1056/NEJMoa2007764 . - DOI - PMC - PubMed

Publication types

Substances